Matthew Tan, MD

Articles

Pegylated Liposomal Doxorubicin: Antitumor Activity in Epithelial Ovarian Cancer or Cancers of Peritoneal Origin

Franco M. Muggia, MD;Tamar Safra, MD;Susan Groshen, PhD;Susan Jeffers, RN;Lynda Roman, MD;Matthew Tan, MD;Laila Muderspach, MD;Alexander Burnett, MD;Silvia C. Formenti, MD;C. Paul Morrow, MD;Michael Amantea, PhD

October 1st 1997

After pegylated liposomal doxorubicin (PEG-LD) (Doxil) was shown to be active in ovarian tumors, several trials were developed at the University of Southern California to determine its safety and efficacy in a variety of gynecologic and peritoneal malignancies. Completed phase I and phase II trials have found PEG-LD to be safe and effective in the treatment of platinum- and paclitaxel-refractory epithelial ovarian carcinoma. A new phase II trial is currently underway in similarly refractory patients with ovarian and other related cancers and various degrees of pretreatment. In addition, the efficacy of PEG-LD is being explored in combination with paclitaxel (Taxol), with cisplatin, and with hyperthermia. [ONCOLOGY 11(Suppl 11):38-44, 1997]